M&G Plc Has $11.49 Million Stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

M&G Plc lifted its position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 2.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 143,565 shares of the company’s stock after buying an additional 4,103 shares during the quarter. M&G Plc owned about 0.28% of PROCEPT BioRobotics worth $11,485,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Sentry Investment Management LLC acquired a new stake in PROCEPT BioRobotics during the 3rd quarter worth about $120,000. Harbor Capital Advisors Inc. acquired a new stake in PROCEPT BioRobotics during the third quarter worth approximately $3,006,000. Americana Partners LLC bought a new stake in PROCEPT BioRobotics in the third quarter worth approximately $1,494,000. Oak Ridge Investments LLC acquired a new position in PROCEPT BioRobotics in the third quarter valued at approximately $1,942,000. Finally, Nisa Investment Advisors LLC boosted its holdings in shares of PROCEPT BioRobotics by 178.3% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,113 shares of the company’s stock worth $89,000 after buying an additional 713 shares in the last quarter. Institutional investors own 89.46% of the company’s stock.

Insider Buying and Selling at PROCEPT BioRobotics

In other news, CEO Reza Zadno sold 288,461 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $91.00, for a total value of $26,249,951.00. Following the transaction, the chief executive officer now owns 258,445 shares in the company, valued at $23,518,495. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Reza Zadno sold 288,461 shares of the business’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $91.00, for a total value of $26,249,951.00. Following the transaction, the chief executive officer now directly owns 258,445 shares of the company’s stock, valued at approximately $23,518,495. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Kevin Waters sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $72.47, for a total transaction of $1,811,750.00. Following the sale, the chief financial officer now owns 96,096 shares of the company’s stock, valued at $6,964,077.12. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 535,353 shares of company stock worth $46,627,426. Insiders own 17.40% of the company’s stock.

Wall Street Analysts Forecast Growth

PRCT has been the topic of a number of research reports. Truist Financial reiterated a “buy” rating and set a $105.00 target price (up previously from $95.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, October 30th. TD Cowen increased their price objective on shares of PROCEPT BioRobotics from $75.00 to $99.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Wells Fargo & Company boosted their target price on PROCEPT BioRobotics from $67.00 to $69.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Piper Sandler reiterated an “overweight” rating and issued a $75.00 price target on shares of PROCEPT BioRobotics in a report on Tuesday, October 8th. Finally, Bank of America boosted their price objective on PROCEPT BioRobotics from $80.00 to $94.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $88.40.

PROCEPT BioRobotics Stock Down 2.0 %

PRCT stock opened at $96.23 on Friday. The stock’s 50 day moving average is $79.03 and its 200-day moving average is $69.62. PROCEPT BioRobotics Co. has a twelve month low of $29.71 and a twelve month high of $99.34. The firm has a market capitalization of $5.02 billion, a PE ratio of -49.35 and a beta of 1.01. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Monday, October 28th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.09. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The firm had revenue of $58.40 million for the quarter, compared to the consensus estimate of $53.30 million. During the same period in the previous year, the firm earned ($0.51) EPS. The business’s revenue for the quarter was up 66.4% compared to the same quarter last year. Sell-side analysts expect that PROCEPT BioRobotics Co. will post -1.74 EPS for the current fiscal year.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).